Key Highlights

● Nasdaq removed Virpax in 2025 for missing the minimum stockholders' Equity requirement, and the company would not appeal.

● Virpax is a preclinical company developing pain treatments, including Probudur for post-operative pain and Envelta for acute and chronic pain.

● Fiscal 2024 net loss was about $12.07 million with no revenue, or $2.84 per diluted share.

● Three directors and the chief financial officer resigned on April 2, 2025, citing no disagreements over operations or policies.

Virpax Pharmaceuticals, Inc. (OTC:VRPX) appears on the over-the-counter market after its shares were removed from Nasdaq in 2025. The reason is straightforward: the company did not meet Nasdaq's minimum stockholders' equity requirement under Listing Rule 5550(b)(1), and a Nasdaq Hearings Panel determined that the listing should end. Reports dated April 4, 2025 said the company would not appeal.

That history explains why a drug developer with several named programmes is now quoted far below its former levels. Data providers show the shares changing hands at fractions of a cent, with a Market Capitalisation of only a few thousand dollars and very thin volume. Those quotations are unreliable, because trading in such Illiquid shares can be sporadic and the figures differ between sources.

What the Business does

Virpax describes itself as a preclinical-stage pharmaceutical company that develops drug-delivery systems aimed at non-opioid, non-addictive pain management and other central nervous system disorders. Its pipeline, as summarised by market data, includes Probudur, a liposomal bupivacaine injection intended for post-operative pain; Envelta, an intranasal enkephalin formulation for acute and chronic pain; and NobrXiol, an intranasal cannabidiol product for rare paediatric epilepsy. Epoladerm and AnQlar complete the list of non-prescription candidates.

Being preclinical means none of these products has reached human efficacy trials that could support a regulatory approval. The sector is healthcare, specifically biotechnology.

The company has also pointed to cooperative research arrangements with the National Institutes of Health and the Department of Defense for selected candidates, according to market data.

Latest verified developments

The most recent company announcements date from the first half of 2025. On March 19, 2025 Virpax announced a Reverse Stock Split intended to address Nasdaq's minimum bid price rule, and around the same time it reported positive preclinical Probudur dose-range findings. Within weeks the board changed sharply: three directors and the chief financial officer resigned on April 2, 2025, stating that they had no disagreements over operations or policies.

Financial picture

For fiscal 2024, aggregators report a net loss of about $12.07 million and no revenue. Diluted loss per share was reported as $2.84. Before the delisting, market data cited a current ratio of 0.63, meaning short-term obligations exceeded liquid assets, and a market capitalisation of roughly $1.18 million.

The company also announced a $6 million public offering that closed in January 2025, according to market data. Such raises typically fund operations for a limited period and can dilute existing holders substantially, which is consistent with the steep decline in the share price over the last year.

Funding, Venue and Litigation Risks Define Virpax Outside Nasdaq

The risks are considerable. Funding is the first: a business with negative Working Capital and no income must raise money or find a partner to continue. Second, Quotation on the over-the-counter market brings lower transparency, wider spreads and difficulty exiting positions. Third, Virpax has faced litigation in the past; a court ruling reported on September 5, 2023 found for plaintiffs Scilex Pharmaceuticals and Sorrento Therapeutics on most claims, with remedies left for later proceedings, and the current status of that matter is not confirmed.

A current annual report, any updated going-concern language, confirmation of its OTC tier, news on Probudur or Envelta development, and any financing terms would clarify the picture. On the evidence available, Virpax is a very small, financially stretched preclinical company rather than an established drug developer.